Cannabis Science (CBIS) Applauds U.S. Congress on Moving to Legalize Hemp Cultivation and Research; Calls Today for Final Senate Passage of Farm Bill and President's Signature into Law

COLORADO SPRINGS, Colo., Feb. 4, 2014 /PRNewswire/ -- Cannabis Science, Inc. (OTC: CBIS), a U.S. Company specializing in cannabis-based pharmaceutical development and related consulting operations, is pleased that the U.S. Congress and President Obama appear positioned to approve the first federal law to legalize hemp cultivation and advanced research on a federal level, creating unprecedented opportunities for the Company to pursue patient-based pharmaceutical solutions for patients.

Last week the U.S. House of Representatives approved the "farm bill" that contains a provision for certain cultivation of industrial hemp for research in a number of U.S. states.  The Senate is expected to approve the measure as soon as today, and President Obama has declared that he will sign the bill into law, changing the legal landscape for the entire hemp industry. 

"As hemp and cannabis both come from the same plant, federal movement on liberalization of hemp cultivation and research will positively impact Cannabis Science's opportunities for pharmaceutical research and development of cannabis and cannabinoid-based pharmaceutical products for patients.  The House has approved the bill, and the Senate is expected vote in favor of it today or tomorrow, with near certain approval from the President.  The Company is formulating its strategy for this regulatory opening to more quickly bring pharmaceutical products to market for the benefit of patients in need," said Chad S. Johnson, Chief Operating Officer and General Counsel of Endocan Corporation.

About Cannabis Science, Inc.
Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.

Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Cannabis Science, Inc.

Dr. Dorothy Bray, CEO & Director
dorothy.bray@cannabisscience.com
Tel: 1.888.777.0658
www.cannabisscience.com
info@cannabisscience.com

Investment Inquiries
Robert Kane, CFO & Director
robert.kane@cannabisscience.com
561.420.4824

SOURCE Cannabis Science, Inc.



RELATED LINKS
http://www.cannabisscience.com

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.